Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May 23;12(5):1336.
doi: 10.3390/cancers12051336.

Therapeutic Approach to Low-Grade Serous Ovarian Carcinoma: State of Art and Perspectives of Clinical Research

Angiolo Gadducci  1 , Stefania Cosio  1
Affiliations
Review

Therapeutic Approach to Low-Grade Serous Ovarian Carcinoma: State of Art and Perspectives of Clinical Research

Angiolo Gadducci et al. Cancers (Basel). .

Abstract

Low-grade serous ovarian carcinoma (LGSOC) is a distinct pathologic and clinical entity, characterized by less aggressive biological behavior, lower sensitivity to chemotherapy and longer survival compared with high-grade serous ovarian carcinoma. LGSOC often harbors activating mutations of genes involved in mitogen activated protein kinase (MAPK) pathway. Patients with disease confined to the gonad(s) should undergo bilateral salpingo-oophorectomy, total hysterectomy and comprehensive surgical staging, although fertility-sparing surgery can be considered in selected cases. Women with stage IA-IB disease should undergo observation alone after surgery, whereas observation, chemotherapy or endocrine therapy are all possible options for those with stage IC-IIA disease. Patients with advanced disease should undergo primary debulking surgery with the aim of removing all macroscopically detectable disease, whereas neoadjuvant chemotherapy followed by interval debuking surgery. After surgery, the patients can receive either carboplatin plus paclitaxel followed by endocrine therapy or endocrine therapy alone. Molecularly targeted agents, and especially MEK inhibitors and Cyclin-dependent kinase (CDK) inhibitors, are currently under evaluation. Additional research on the genomics of LGSOC and clinical trials on the combination of MEK inhibitors with hormonal agents, other molecularly targeted agents or metformin, are strongly warranted to improve the prognosis of patients with this malignancy.

Keywords: chemotherapy; endocrine therapy; low grade ovarian serous carcinoma; mitogen activated protein kinase (MAPK); molecularly-targeted agents; surgery.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Malpica A., Deavers M.T., Lu K., Bodurka D.C., Atkinson E.N., Gershenson D.M., Silva E.G. Grading ovarian serous carcinoma using a two tier system. Am. J. Surg. Pathol. 2004;28:496–504. doi: 10.1097/00000478-200404000-00009. - DOI - PubMed
    1. Gershenson D.M., Sun C.C., Lu K.H., Coleman R.L., Sood A.K., Malpica A., Deavers M.T., Silva E.G., Bodurka D.C. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol. 2006;108:361–368. doi: 10.1097/01.AOG.0000227787.24587.d1. - DOI - PubMed
    1. Plaxe S.C. Epidemiology of low-grade serous ovarian cancer. Am. J. Obstet. Gynecol. 2008;198:459.e1–459.e9. doi: 10.1016/j.ajog.2008.01.035. - DOI - PubMed
    1. Matsuo K., Machida H., Grubbs B.H., Sood A.K., Gershenson D.M. Trends of low-grade serous ovarian carcinoma in the United States. J. Gynecol. Oncol. 2018;29:e15. doi: 10.3802/jgo.2018.29.e15. - DOI - PMC - PubMed
    1. Schlumbrecht M.P., Sun C.C., Wong K.N., Broaddus R.R., Gershenson D.M., Bodurka D.C. Clinicodemographic factors influencing outcomes in patients with low-grade serous ovarian carcinoma. Cancer. 2011;117:3741–3749. doi: 10.1002/cncr.25929. - DOI - PMC - PubMed

LinkOut - more resources